pyridoxal phosphate has been researched along with Diabetic Nephropathies in 7 studies
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).
pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied predictors of homocysteine levels and correlations between homocysteine and (micro-)albuminuria, retinopathy, and history of cardiovascular disease in normotensive NIDDM subjects under stable metabolic control." | 7.70 | Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. ( Odekerken, DA; Rakic, M; Sijbrands, EJ; Silberbusch, J; Slaats, EH; Smulders, YM; Stehouwer, CD; Treskes, M, 1999) |
| "We studied predictors of homocysteine levels and correlations between homocysteine and (micro-)albuminuria, retinopathy, and history of cardiovascular disease in normotensive NIDDM subjects under stable metabolic control." | 3.70 | Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. ( Odekerken, DA; Rakic, M; Sijbrands, EJ; Silberbusch, J; Slaats, EH; Smulders, YM; Stehouwer, CD; Treskes, M, 1999) |
| "Patients with diabetic nephropathy are at elevated cardiovascular risk." | 1.32 | Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, EJ | 1 |
| Greene, T | 1 |
| Spitalewiz, S | 1 |
| Blumenthal, S | 1 |
| Berl, T | 1 |
| Hunsicker, LG | 2 |
| Pohl, MA | 1 |
| Rohde, RD | 1 |
| Raz, I | 1 |
| Yerushalmy, Y | 1 |
| Yagil, Y | 1 |
| Herskovits, T | 1 |
| Atkins, RC | 1 |
| Reutens, AT | 1 |
| Packham, DK | 1 |
| Lewis, JB | 1 |
| Cetin, E | 1 |
| Civelek, S | 1 |
| Andican, G | 1 |
| Candan Polizzi, F | 1 |
| Yumuk, V | 1 |
| Burçak, G | 1 |
| Friedman, AN | 1 |
| Selhub, J | 1 |
| Bostom, AG | 1 |
| Nakamura, S | 1 |
| Li, H | 1 |
| Adijiang, A | 1 |
| Pischetsrieder, M | 1 |
| Niwa, T | 1 |
| Rahbar, S | 1 |
| Smulders, YM | 1 |
| Rakic, M | 1 |
| Slaats, EH | 1 |
| Treskes, M | 1 |
| Sijbrands, EJ | 1 |
| Odekerken, DA | 1 |
| Stehouwer, CD | 1 |
| Silberbusch, J | 1 |
| Hayakawa, M | 1 |
| Shibata, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00021918] | 0 participants | Observational | 2001-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pyridoxal phosphate and Diabetic Nephropathies
| Article | Year |
|---|---|
Pyridorin in type 2 diabetic nephropathy.
Topics: Aged; Creatinine; Cystatin C; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method | 2012 |
Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2013 |
5 other studies available for pyridoxal phosphate and Diabetic Nephropathies
| Article | Year |
|---|---|
Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholester | 2004 |
Pyridoxal phosphate prevents progression of diabetic nephropathy.
Topics: Administration, Oral; Animals; Diabetic Nephropathies; Female; Fibronectins; Glycation End Products, | 2007 |
Novel inhibitors of glycation and AGE formation.
Topics: Animals; Ascorbic Acid; Body Weight; Butyrates; Cholesterol; Creatinine; Diabetes Mellitus, Experime | 2007 |
Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Albuminuria; Analysis of Variance; Blood Pressure; Cardiovascular | 1999 |
The in vitro and in vivo inhibition of protein glycosylation and diabetic vascular basement membrane thickening by pyridoxal-5'-phosphate.
Topics: Animals; Basement Membrane; Blood Glucose; Body Weight; Diabetic Nephropathies; Fructosamine; Glycat | 1991 |